# Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

> **NCT02920541** · PHASE1 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 48 (actual)

## Conditions studied

- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** S 055746

## Key facts

- **NCT ID:** NCT02920541
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-05-24
- **Final completion:** 2018-05-24
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920541, "Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02920541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*